Global blockchain in the genomic data management markets until 2030


Dublin, 12 December 2018 (GLOBE NEWSWIRE) – The report "Blockchain in genomic data management: market analysis and competitive analysis, 2018-2030" has been added of offer.

"Blockchain in Genomic Data Management: Market Landscape and Competitive Insights, 2018-2030" presents an extensive study of industry actors offering blockchain platforms for the storage and management of genomic data.

The success of the Human Genome project has led to the generation of large volumes of genomic data, widely used in biotechnology and medical research. In addition, advances in high-throughput gene sequencing technologies have enabled scientists to accelerate the genome sequencing process and also achieve significant cost benefits.

In fact, it is estimated that by 2025 about 15% of the world's population will have sequenced their genomes, resulting in the generation of several zettabytes of data.

However, at the moment, there are not many reliable and secure data management resources that offer secure storage, uninterrupted information exchange and a reliable transaction platform for large volumes of genomic and clinical data. Therefore, at this stage, it has become important to develop and establish the tools and technologies necessary to effectively contribute to the processing and analysis of the above information and make it easily accessible to physicians, scientists, pharmaceutical companies and other interested parties.

Key points

  • The current market landscape is relatively niche with a limited number of companies offering blockchain platforms for managing genomic data. Of the total number of players involved, over 35% are based in North America, mainly in the United States. Examples of players based in this region include (in alphabetical order, no specific selection criteria) EncrypGen, GnoMine, LunaDNA and Nebula Genomics. It is worth pointing out that companies are also based in developing regions such as Brazil, India, Israel, Russia, Singapore and South Korea.
  • Most companies (86%) are engaged in providing services mainly to pharmaceutical operators and research institutes. In addition, companies also offer genomic data management via blockchain platforms to other key stakeholders such as data owners, software developers and insurers.
  • All companies involved in this sector offer genomic data sharing / transfer services to data owners and data buyers. In addition, companies claim to offer services such as the storage of genomic data (87%), anonymity of data (87%), incentives for sharing genomic data (87%), complete sequencing of the genome (53%) and genetic counseling (27%), exclusively to data owners. In addition, the services offered to data buyers include access to genomic data sets and analysis of genomic data.
  • An analysis of over 1,750 tweets on social media platforms and opinions expressed by industry experts highlight unaddressed concerns related to the management of genomic data; these include privacy issues, unsafe transactions and lack of security / reliability related to stored genomic data. It is worth mentioning that these challenges can be addressed through the exchange of data on blockchain platforms. A full tweet analysis showed that 85% was positive, suggesting that, at this stage, stakeholders are optimistic about the potential future of blockchain genomic data management platforms.
  • In order to improve the adoption of blockchain platforms in the management of genomic data, industry stakeholders are exploring a variety of innovative marketing strategies. The most popular marketing strategies that are implemented include the use of social media platforms to spread awareness about blockchain platforms, online media and growing participation in global events, such as conferences, to achieve the required visibility on the market.
  • The total market capitalization of currencies is currently estimated at around USD 400 million – USD 750 million, based on the total maximum bid, the circulation offer and the price (in USD) of the utility token of several companies engaged in this sector. Considering that such platforms are readily adopted in the health sector, the above value is expected to increase significantly over the long term.
  • Overall, the market for genomic data management using blockchain platforms is expected to increase at an annualized rate of 43.5% between 2018 and 2030. While the current opportunity is higher for applications related to the development of personalized medicines , its scope in other application areas (it is expected that the services of advanced genetic analysis and identification of genotypic markers to allow a better diagnosis) grow at a relatively faster rate in the forecast period.

Main topics covered

1. Preface
1.1. Overview of the chapter
1.2. Research methodology
1.3. Schemes of the chapter

2. Executive summary

3. Introduction
3.1. Overview of the chapter
3.2. Blockchain concept
3.3. Potential blockchain applications in the healthcare industry
3.4. Overview and importance of genomic data
3.5. Historical evolution of genomic tests
3.6. Need to share genomic data on Blockchain platforms
3.6.1. Process of sharing genomic data on Blockchain platforms Role of utility tokens Token distribution events Role of compression tools
3.6.2. Disputes concerning the sharing of genomic data on Blockchain platforms
3.7. Advantages and limitations of genomic data sharing on Blockchain platforms

4. Panorama of the market
4.1. Overview of the chapter
4.2. Blockchain in the management of genomic data: list of players in the sector
4.2.1. Analysis by year of establishment
4.2.2. Analysis by geographical position
4.2.3. Analysis by company size
4.2.4. Analysis by geographical position and year of establishment
4.2.5. Analysis by company size and geographical position
4.2.6. Analysis by type of business model
4.2.7. Analysis by type of services offered
4.2.8. Analysis by type of end users
4.2.9. Analysis by type of services offered and geographical position
4.2.10. Analysis by type of services offered and end users

5. Company profiles
5.1. Overview of the chapter
5.2. Block23
5.3. DNAtix
5.4. EncrypGen
and more …

6. Emerging trends on social media
6.1. Overview of the chapter
6.2. Blockchain in the management of genomic data: trends on Twitter
6.2.1. Historical trends in the volume of tweets
6.2.2. Cumulative year-wise activity
6.2.3. Trend words / phrases on Twitter
6.2.4. Trending utility traces on Twitter
6.2.5. Popular players on Twitter
6.2.6. Most of the prolific contributors on Twitter
6.2.7. Sentiment analysis
6.3. Concluding remarks

7. Analysis of the needs of the parties involved
7.1. Overview of the chapter
7.2. Needs of stakeholders (pharmaceutical companies / research institutes / data owners / government agencies / insurers)
7.2.1. Qualitative analysis of current and future needs

8. Go-To-Market Strategy
8.1. Overview of the chapter
8.2. Blockchain in Genomic Data Management: marketing strategies
8.2.1. Participation in global events
8.2.2. Marketing on social media platforms
8.2.3. Marketing on online printing / printing platforms
8.2.4. Adoption of strategic business models B2C business model B2B business model C2B business model
8.2.5. Undertake promotional activities
8.3. Concluding remarks

9. Analysis of market capitalization
9.1. Overview of the chapter
9.2. Methodology
9.2.1. Key assumptions
9.3. Analysis of market capitalization for different utility tokens: analysis of 3D bubbles
9.4. Concluding remarks

10. Blockchain in cases of use of genomic data management and evaluation of opportunities
10.1. Overview of the chapter
10.2. Blockchain in Genomic data management: use cases
10.3. Blockchain in the management of genomic data: evaluation of market opportunities
10.3.1. Methodology and key hypothesis
10.3.2. Blockchain in Genomic data management: market opportunities, 2018-2030

11. Analysis of recent trends
11.1. Overview of the chapter
11.2. Blockchain in Genomic Data Management: Venture Capital Funding Activity
11.2.1. Types of financing
11.2.2. List of loans and investments Summary of financing and investments
11.3. Blockchain in the management of genomic data: partnership activities
11.3.1. List of partnerships and collaborations Summary of partnerships and collaborations
11.4. Blockchain in the management of genomic data: recent news activity
11.4.1. List of recent news Analysis by key area
11.5. Blockchain in the management of genomic data: recent / upcoming global events
11.5.1. List of recent / upcoming global events Analysis by year of occurrence Analysis by geography Analysis by type of event
11.6. Blockchain in Genomic Data Management: transcripts of public discussions
11.6.1. Dennis Grishin, Chief Scientific Officer / Co-founder of Nebula Genomics
11.6.2. Henry Ines, Chief Executive Officer, Shivom
11.6.3. Ofer to Lidsky, Co-founder, Chief Executive Officer and Chief Technology Officer, DNAtix
11.6.4. David Kerr, Chief Executive Officer, Block23
11.6.5. Alex Gorbachev and Nikolay Kulemin, co-founders, Zenome
11.7. Concluding remarks

12. Executive deepenings
12.1. Overview of the chapter
12.2. EncrypGen
12.2.1. Snapshot of the company
12.2.2. Transcript of the interview: David Koepsell, Chief Executive Officer
12.3. SimplyVital Health
12.3.1. Snapshot of the company
12.3.2. Transcript of the interview: Jake Dreier, director of growth and operations
12.4.1. Snapshot of the company
12.4.2. Transcript of the interview: Aldo de Pape, Chief Executive Officer and Louis Gooden, analyst

13. Appendix 1: Tabulated data

14. Appendix 2: List of companies and organizations

Featured companies

  • 23andMe
  • Ancestry
  • Anorak Ventures
  • ARCH Venture Partners
  • Biologix Group
  • Block23
  • Increase VC
  • Bridge Link Capital
  • CollinStar Capital
  • Cdigo46
  • DigitalX
  • Discovery Capital Management
  • DNAtix
  • eMQT
  • Emrify
  • EncrypGen
  • Enigma Technologies
  • F-Prime Capital Partners
  • The capital of Fenbushi
  • Gene BlockChain
  • Gene Whisper
  • Genecoin
  • Genetic technologies
  • gnomine
  • Google
  • GreatPoint Ventures
  • Wizz health
  • Heartbeat Labs
  • Hemi Ventures
  • Hemisphere Ventures
  • Hikma Ventures
  • Capital of Hoperidge
  • Illumina Ventures
  • Ironside Capital
  • Khosla Ventures
  • Longenesis
  • LunaDNA
  • Macrogen
  • MapMyGenome
  • Mayfield
  • Med-Metrix
  • MicroVentures
  • Mirae Asset
  • Genomic Nebula
  • Shivom
  • SimplyVital Health
  • SingularityNET
  • Spherity
  • Toro Risk Consulting Group
  • Veritas Technologies
  • Windham Venture Partners
  • WuCi NextCODE genomics
  • X Genomics
  • Fund for the innovation of the IOG
  • Zenome

For more information on this report, visit

Research and Markets also offers customized search services that provide targeted, complete and tailored searches.

Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For the free call of the United States 1-800-526-8630
For GMT + 353-1-416-8900 office calls
Related topics: Genomics, data storage and management, Bitcoin  
[ad_2]Source link